2 October 2024 in Genome Research
Fewer than half of individuals with a suspected Mendelian or monogenic condition receive a precise molecular diagnosis after comprehensive clinical genetic testing. Improvements in data quality and costs have heightened interest in using long-read sequencing (LRS) to streamline clinical genomic testing, but the absence of control data sets for variant filtering and prioritization has made tertiary analysis of LRS data challenging. To address this, the 1000 Genomes Project (1KGP) Oxford Nanopore Technologies Sequencing Consortium aims to generate LRS data from at least 800 of the 1KGP samples. Our goal is to use LRS to identify a broader spectrum of variation so we may improve our understanding of normal patterns of human variation. Here, we present data from analysis of the first 100 samples, representing all 5 superpopulations and 19 subpopulations. These samples, sequenced to an average depth of coverage of 37× and sequence read N50 of 54 kbp, have high concordance with previous studies for identifying single nucleotide and indel variants outside of homopolymer regions. Using multiple structural variant (SV) callers, we identify an average of 24,543 high-confidence SVs per genome, including shared and private SVs likely to disrupt gene function as well as pathogenic expansions within disease-associated repeats that were not detected using short reads. Evaluation of methylation signatures revealed expected patterns at known imprinted loci, samples with skewed X-inactivation patterns, and novel differentially methylated regions. All raw sequencing data, processed data, and summary statistics are publicly available, providing a valuable resource for the clinical genetics community to discover pathogenic SVs.
1 September 1996 in British Journal of Dermatology
1 November 1999 in Journal of Burn Care & Rehabilitation
Tissue culture media used by skin and tissue banks to store tissue were tested, with and without antimicrobial mixtures, for their ability to inhibit the growth of bacteria during incubation at refrigerator temperatures. Reductions in bacterial load were found after incubation at 4 degrees C in both the basal tissue culture media with and without the addition of antimicrobial mixtures. The presence of antimicrobials enhanced the degree and rapidity of reduction. Variations occurred among the different formulations, with or without added antimicrobials. No one formulation for either the basal tissue culture medium or antimicrobial mixture was ideal. Methods described in this study can be used to establish optimum basal medium and antimicrobial mixture formulations for general use by skin and tissue banks.
28 October 2026 in medRxiv
Sequence-to-omics (S2O) predictions and molecular outliers provide complementary evidence to prioritize functional rare variants and facilitate rare disease diagnoses. However, current approaches do not integrate both lines of evidence. We present Watershed-DL, a framework that integrates S2O predictions of variant effects from DNA and protein sequence with multi-omic outliers to identify large-effect rare variants. We applied Watershed-DL to 1000 Genomes samples with RNA-seq (n=1,030) to prioritize rare variants underlying expression, splicing, and allele-specific expression outliers, and, using a separate peak-level model, to samples with ATAC-seq (n=174) for chromatin accessibility outliers. Compared to a model without S2O predictions, Watershed-DL increased the number of prioritized variants by 61.4%, and S2O features were weighted highly in the model across all molecular signals. Prioritized variants were over 60-fold enriched for ClinVar pathogenic classifications. Matching prioritized variants to known pathogenic variants in the same gene with a concordant molecular effect identified 331 additional candidate recessive disease alleles. Applying this framework to the GREGoR rare disease cohort with RNA-seq (n=677) prioritized previously reported causal variants across 10 solved cases and identified 451 candidate variants in unsolved cases, including a diagnostic variant in PPP1R12A and a novel candidate disease gene, ATP5PF .